Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJunnan LiDZDongfeng ZengYYYi‐Hsin Yang

Discussion

Loading...

Member takes

Overview

Retrospective study shows ixazomib improves progression-free survival in newly diagnosed multiple myeloma patients, indicating manageable adverse events.

Key Points

  • To evaluate the efficacy and safety of ixazomib-based maintenance therapy in Chinese patients with newly diagnosed multiple myeloma.
  • Multicenter retrospective analysis across four centers in Southwest China
  • Patients stratified by transplant status (ASCT vs non-ASCT)
  • Evaluated progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier method
  • Assessed remission rates and adverse events
  • Median follow-up of 23 months with a median duration of therapy of 7 months
  • In ASCT cohort, median PFS was 36 months and overall survival not reached
  • VGPR rates increased from 81.2% to 90.6% after ixazomib maintenance in ASCT cohort
  • Non-ASCT cohort had a median PFS of 28 months; VGPR rates improved from 65.7% to 86.9%
  • Common adverse events included neutropenia (13.7%) and anemia (7.5%)

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e244https://doi.org/10.1182/blood-2025-7544
View Full Paper
Ask AI
Bookmark
Share